A major breakthrough for NovalGen, announcing first clinical data from the ongoing Phase 1/2 study of NVG-111 in patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.
London, United Kingdom, May 26, 2022 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announces first clinical data from the ongoing Phase 1/2 study of NVG-111, a novel ROR1 targeting bispecific antibody T cell engager, in patients with relapsed and refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting McCormick Place, Chicago, IL, June 3 to 7, 2022. The Company will also be presenting additional clinical data at the conference.
Read the full story from NovalGen here.
We make UCL’s research physical and life sciences ideas happen.
